Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Asset Writedowns and Impairment (2024 - 2025)

TriSalus Life Sciences (TLSI) has 2 years of Asset Writedowns and Impairment data on record, last reported at $34000.0 in Q3 2025.

  • For Q3 2025, Asset Writedowns and Impairment changed N/A year-over-year to $34000.0; the TTM value through Sep 2025 reached $317000.0, changed N/A, while the annual FY2024 figure was $187000.0, N/A changed from the prior year.
  • Asset Writedowns and Impairment reached $34000.0 in Q3 2025 per TLSI's latest filing, down from $57000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $187000.0 in Q4 2024 and bottomed at $34000.0 in Q3 2025.